• BCG is known to interfere with Cystoscopy and Cytology leading to equivocal test results.
  • In a pivotal study where a positive cystoscopy (some-times without biopsy) was considered positive, UroVysion demonstrated 71% overall sensitivity and 92% sensitivity in BCG treated patients. 3
  • UroVysion allows for more accurate patient monitoring.
UroVysion PROVIDES RESULTS YOU CAN COUNT ON
  • On average, 45% of cytology results are non-determinant. 4
  • 100% of UroVysion results are unambiguous.
  • The UroVysion test can provide ongoing monitoring to detect recurrent bladder cancer early and accurately - vital information you need to treat your patients sooner and more appropriately.
References
1 Halling et al., AUA Poster 665, 2001.

2 Halling KC, King W, Sokolova IA, et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. Journal of Urology. 2000; 164:1768-1775.

3 UroVysion Package Insert.

4 Bastacky S, Ibrahim S, Wilczynski S, Murphy WM. The accuracy of urinary cytology in daily practice. Cancer Cytopathology. 1999;87:118-128.
The UroVysion Bladder Cancer Kit (UroVysion Kit) is designed to detect aneuploidy for chromosomes 3, 7, 17, and loss of the 9p21 locus via fluorescence in situ hybridization (FISH) in urine specimens from persons with hematuria suspected of having bladder cancer. Results from the UroVysion Kit are intended for use, in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer.